Medigen Vaccine Biologics (6547) — Cash Flow-to-Debt Ratio
Medigen Vaccine Biologics (6547) has a Cash Flow-to-Debt Ratio of 0.22x as of December 2025, meaning its operating cash flow of NT$101.08 Million could theoretically repay 0% of its total liabilities (NT$454.64 Million) in one year. See Medigen Vaccine Biologics free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Medigen Vaccine Biologics Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Medigen Vaccine Biologics across 14 annual periods. Also explore Medigen Vaccine Biologics annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Medigen Vaccine Biologics (2012–2025)
Year-by-year debt coverage analysis for Medigen Vaccine Biologics. For market capitalisation and broader financial context, see market cap of Medigen Vaccine Biologics.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.11x | NT$-49.09 Million | NT$454.64 Million | ▼ -236.2% |
| 2024 | 0.08x | NT$40.75 Million | NT$513.92 Million | ▲ +137.3% |
| 2023 | -0.21x | NT$-477.75 Million | NT$2.25 Billion | ▲ +55.2% |
| 2022 | -0.47x | NT$-1.10 Billion | NT$2.32 Billion | ▼ -151.0% |
| 2021 | 0.93x | NT$579.89 Million | NT$622.95 Million | ▲ +155.1% |
| 2020 | -1.69x | NT$-589.97 Million | NT$349.40 Million | ▼ -232.2% |
| 2019 | -0.51x | NT$-462.65 Million | NT$910.28 Million | ▲ +18.5% |
| 2018 | -0.62x | NT$-356.33 Million | NT$571.10 Million | ▼ -76.9% |
| 2017 | -0.35x | NT$-217.03 Million | NT$615.41 Million | ▲ +24.9% |
| 2016 | -0.47x | NT$-163.37 Million | NT$347.90 Million | ▼ -167.1% |
| 2015 | 0.70x | NT$216.26 Million | NT$309.19 Million | ▲ +118.5% |
| 2014 | -3.78x | NT$-513.98 Million | NT$135.95 Million | ▼ -1.7% |
| 2013 | -3.72x | NT$-72.36 Million | NT$19.46 Million | ▼ -1404.9% |
| 2012 | -0.25x | NT$-5.47 Million | NT$22.15 Million | — |